Almac and University College London team up on metagenomics

R&D work will be carried out jointly between Almac and the departments of Biochemical Engineering and Chemistry at UCL, focused specifically on metagenomics and novel enzyme discovery
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
CRAIGAVON, U.K. and LONDON—Northern Ireland-based Almac's biocatalysis group has secured what it call "a prestigious" UK Biotechnologyand Biological Sciences Research Council program with University College London (UCL) focusedon metagenomics and novel enzyme discovery.
The research and developmentwork under the deal will be carried out jointly between Almac and thedepartments of Biochemical Engineering and Chemistry at UCL, "with high-level input from two world leaders in the field of biocatalyst discoveryand application, Professors John Ward and Helen Hailes," Almac says.
"This clearly adds further depth to our expertise andcomplements our recent collaboration with DSM in accessing diverseenzyme collections,"
said Dr.Tom Moody, Almac's head of Biocatalysis & Isotope Chemistry.

"We are very excited to continue working with Almac onthis prestigious project, building on many years of collaboration andpartnership. Indeed, this project will see our internal capabilitiesfurther developed with true industrial needs in our vision," added Ward.
Continue reading below...
Illustration of diverse healthcare professionals interacting with digital medical data and health records on virtual screens.
WebinarsAccelerating rare disease clinical trials
Explore how a rare kidney disease trial achieved faster patient enrollment with data-informed strategies and collaborative partnerships.
Read More
Theapplication of biocatalysis technology to the pharmaceutical and finechemical industries is continuing to grow year on year and this trend ismirrored in the increasing number of synthetic projects being carriedout by the biocatalysis group in Almac, the company says.
As Almac puts it, "Theonly limitation of biocatalysis is in the number of diverse enzymesavailable in a given enzyme class, which dictates both the substraterange and the stereoselectivity observed for a desired chemicaltransformation. The majority of enzymes used in biocatalysis are derivedfrom microbial sources. However, it is known that only a tinypercentage (as low as 0.1% from soil samples) of bacteria present in anenvironmental sample can be cultured and isolated."
Continue reading below...
A scientist wearing gloves handles a pipette over a petri dish and a color-coded microplate in a laboratory setting.
Application NoteThe unsung tools behind analytical testing success
Learn how fundamental laboratory tools like pipettes and balances support analytical precision.
Read More
Reportedly, metagenomics,a culture-independent technique used to extract the total DNA from anenvironment, can circumvent this problem and allow access up to 99 percent ofenzyme genes present in environmental samples. Work previously carriedout at UCL has allowed a series of metagenomes to be obtained from"various unusual sources," as Almac puts it.
The use of bioinformatic tools developed byWard with Prof. Christine Orengo of the Structural and MolecularBiology department at UCL will allow the metagenomes concerned to bemined for enzymes usable in both synthetic chemistry and syntheticbiology projects.
"The need for more diverse enzymes has never beengreater and this research programme further emphasises Almac'scommitment to UK research and to biocatalysis development," Moody said.
"The project will mainly focus on transaminase and cytochrome P450senzymes. We will identify, clone and express these enzymes beforecarrying out extensive screening against panels of 'typical'pharmaceutical and fine chemical substrates. This should enable us toidentify novel and commercially useful enzyme biocatalysts. As thefollow-on step, directed evolution at Almac will enable furtherdevelopment of the lead enzymes concerned."
Continue reading below...
A 3D rendering of round clear cells with multiple red round nodules in each cellular center representing nuclei, suspended in a liquid, clear backdrop.
WhitepaperAutomating 3D cell selection
Discover precise automated tools for organoid and spheroid handling.
Read More
SOURCE: Almac news release

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up of a researcher using a stylus to draw or interact with digital molecular structures on a blue scientific interface.
When molecules outgrow the limits of sketches and strings, researchers need a new way to describe and communicate them.
Portrait of Scott Weitze, Vice President of Research and Technical Standards at My Green Lab, beside text that reads “Tell us what you know: Bringing sustainability into scientific research,” with the My Green Lab logo.
Laboratories account for a surprising share of global emissions and plastic waste, making sustainability a priority for modern research.
3D illustration of RNA molecules on a gradient blue background.
With diverse emerging modalities and innovative delivery strategies, RNA therapeutics are tackling complex diseases and unmet medical needs.
Drug Discovery News September 2025 Issue
Latest IssueVolume 21 • Issue 3 • September 2025

September 2025

September 2025 Issue

Explore this issue